Suchergebnisse - "González, Yolanda"

PubPharm (7)

1

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

enthalten in: Blood | 2016

von Paiva, B. | Cedena, M. | Puig, N. | +27

2

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells : a new model to understand chemoresistance

enthalten in: Blood | 2016

von Paiva, B. | Corchete, L. | Vidriales, M. | +87

3

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

enthalten in: Blood | 2016

von Mateos, M. | Martínez-López, J. | Hernández, M. | +21

CommentIn: Blood. 2016 Jan 28;127(4):375-6. - PMID 26823507

4

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients : do we still need alkylators?

enthalten in: Blood | 2014

von Mateos, M. | Oriol, A. | Martínez-López, J. | +20

5

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

enthalten in: Blood | 2012

von Mateos, M. | Oriol, A. | Martínez-López, J. | +21

6

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma : a randomized phase 3 PETHEMA/GEM study

enthalten in: Blood | 2012

von Rosiñol, L. | Oriol, A. | Teruel, A. | +80

7

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma : a randomised trial

enthalten in: The Lancet. Oncology | 2010

von Mateos, M. | Oriol, A. | Martínez-López, J. | +26

CommentIn: Lancet Oncol. 2010 Oct;11(10):909-10. - PMID 20739219

1
[1]